Shire makes milestone payment to D-Pharm for anticonvulsant
Shire Pharmaceuticals of the UK has made an undisclosed milestonepayment to Israel's D-Pharm as a result of progress in the two firms' Phase II trial of SPD 421 as an add-on therapy in the treatment of complex partial seizures.
SPD 421, formerly known as DP-VPA, is a phosphatidylcholine conjugate of valproic acid, a drug that is already widely used for the treatment of epilepsy. Addition of PC to valproic acid turns it into a prodrug that, it is claimed, exerts its anticonvulsant effects in direct response to metabolic activity at the epilepsy focus in the brain.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze